



## Prevalence and Molecular characterization of *Cryptosporidium* spp. in Humans at Sohag Governorate, Egypt

SALWA G. A. OMRAN<sup>1</sup>, AHMED K. DYAB<sup>2a,b</sup>, AMAL M. AHMED<sup>1</sup>, AYMAN A. EL-BADRY<sup>3</sup> and AMAL A. ABDEL-MAWGOOD<sup>1</sup>

1- Department of Medical Parasitology, Faculty of Medicine, Sohag University

2a- Department of Medical Parasitology, Faculty of Medicine, Assiut University, Assiut

2B- Department of Parasitology, School of Veterinary Medicine, Badr University , Assiut

3-Department of Microbiology-Medical Parasitology Section, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia

### Abstract

**Background:** Cryptosporidiosis is a global infection caused by *Cryptosporidium*, which infects various vertebrates and humans, and causes gastroenteritis with varying severity. Several *Cryptosporidium* spp. with different genotypes and subtypes are implicated in human cryptosporidiosis.

**Objective:** estimate the prevalence of *Cryptosporidium* species in Sohag, assess its occurrence among various patient groups, and analyze the relationship between *Cryptosporidium* infections and associated risk factors and assessed the genetic diversity of *Cryptosporidium* spp in Humans at Sohag Governorate, Egypt

**Patients and Methods:** A total of 245 human stool samples were collected from patients attending the outpatient clinics of Sohag hospitals. The collected samples were examined microscopically by direct smear and modified Ziehl-Neelsen stain (MZN). All positive *Cryptosporidium* samples detected by MZN were genotyped using nested polymerase chain reaction-restriction fragment length polymorphism (nPCR-RFLP) targeting cowp gene encoding *Cryptosporidium* oocyst wall protein (Cowp).

**Results:** *Cryptosporidium* was detected in 20% (49/245) of the examined samples using MZN. Only 2/49 (4%) of samples positive by microscopy were successfully amplified using cowp gene. All amplified samples were confirmed as *C. hominis* by nPCR-RFLP analysis of the cowp gene. Significant associations were found between cryptosporidiosis and age, residence and patient categories.

**Conclusion:** The identification of *C. hominis* indicates anthroponotic transmission. the relatively low prevalence of *Cryptosporidium* underscores the positive impact of public health measures implemented during and after COVID-19 pandemic on reducing parasitic infections.

**Keywords:** Cryptosporidium, *C. hominis*, Sohag, nested PCR-RFLP, sequencing

**DOI :** 10.21608/SMJ.2025.347066.1520

**Received:** December 11, 2024

**Accepted:** December 25, 2024

**Published:** January 01, 2025

**Corresponding Author:** Salwa Gamal Ahmed

**E.mail:** [salwa.omran1990@gmail.com](mailto:salwa.omran1990@gmail.com)

**Citation:** Salwa Gamal Ahmed, et al., Prevalence and Molecular characterization of *Cryptosporidium* spp. in Humans at Sohag Governorate, Egypt SMJ,2025 Vol. 29 No (1) 2025: 41- 56

**Copyright:** Salwa Gamal Ahmed, et al Instant open access to its content on principle Making research freely available to the public supports greater global exchange of research knowledge. Users have the right to read, download, copy, distribute, print or share the link Full texts



## Introduction

Cryptosporidiosis is a global infection caused by the protozoan *Cryptosporidium*, which infects various vertebrates, including humans. It is primarily transmitted through the fecal-oral route by ingesting viable oocysts from contaminated food or water. While waterborne transmission is well-documented, the natural reservoir and exact infection route of *Cryptosporidia* remain unclear.<sup>(1)</sup>

*Cryptosporidium* causes acute gastroenteritis, abdominal pain, and diarrhea. The severity of symptoms varies with the host's immune status. Healthy individuals usually have self-limiting watery diarrhea, while young children in developing countries may face prolonged diarrhea and malnutrition. Immunocompromised individuals can experience severe, chronic, and potentially fatal cryptosporidiosis.<sup>(2)</sup>

Currently, there are 41 species of *Cryptosporidium*, with over 60 genotypes. Each species has distinct sources of infection, transmission routes, and levels of pathogenicity. Species identification is crucial for assessing local transmission risks and implementing control measures to reduce exposure to infectious oocysts. In humans, nearly 20 species have been identified, with *C. hominis* and *C. parvum* responsible for 90% of infections, leading to nearly a million deaths annually. Other species like *C. felis*, *C. meleagridis*, *C. canis*, *C. suis*, and *C. muris* can also infect humans. *C. hominis* is transmitted solely between humans (anthroponotic), while *C. parvum* causes zoonotic infections in both humans and animals.<sup>(3)</sup>

*Cryptosporidium* infection causes over 50,000 deaths annually and is more prevalent in developing countries. The epidemiological features of human cryptosporidiosis in developing countries differ from those in developed countries due to higher endemicity, lower hygiene levels, and less intensive animal farming.<sup>(4)</sup>

During the COVID-19 pandemic, increased hygiene practices resulted in a significant decrease in gastrointestinal illnesses, including cryptosporidiosis. This underscores the effectiveness of improved public health measures in controlling infectious diseases, especially in endemic areas.<sup>(5)</sup>

Microscopy with acid-fast staining is the primary global screening technique for diagnosing *Cryptosporidium*, especially in rural areas, due to its cost-effectiveness and high sensitivity. However, it cannot identify the specific species or

subspecies. Advanced molecular genetics tools can identify and subtype *Cryptosporidium* species.<sup>(6)</sup>

The present study aimed to estimate the prevalence of *Cryptosporidium* species in Sohag, assess its occurrence among various patient groups, and analyze the relationship between *Cryptosporidium* infections and associated risk factors and assessed the genetic diversity of *Cryptosporidium spp.*

## Material and Methods

A cross-sectional study was performed on fecal samples collected during the period between March 2022 to February 2024, Microscopic examinations carried out in the Medical Parasitology Research Laboratory, Faculty of Medicine, Sohag University, Egypt. Copro-nested (n) PCR-RFLP assay was performed in Molecular Medical Parasitology Lab., Department of Medical Parasitology, Faculty of Medicine, Cairo University, Egypt.

**Samples collection:** A total of 245 human fecal samples were collected from patients attending the outpatient clinics of Sohag hospitals (Sohag University Hospitals- Endemic Diseases Hospital-Sohag Oncology Institute). The patients were of different ages: 124 Children (2 to 12 years old), 27 Adolescents (13 to 19 years old), 26 Young Adults (20 to 35 years old), 38 Middle age (36 to 55 years old), 30 old age ( $\geq 56$  years old); of both sexes, and different immune status. A predesigned questionnaire containing demographic, clinical and environmental data such as the source of drinking water and animal contact was fulfilled for each patient.

**Fecal samples:** Fresh samples were collected in 100 ml clean, labeled containers. Each sample was divided into three portions; a small part for direct smear examination, another part was preserved in tight containers using 7% formalin for microscopic examination and staining, and the third portion was stored at  $-20^{\circ}\text{C}$  in Eppendorf tubes for molecular studies.

**Microscopic examination:** All collected samples were examined microscopically using direct wet smear, formalin-ethyl acetate sedimentation concentration technique and MZN stain.<sup>(7)</sup>

**Genomic DNA extraction from fecal samples:** DNA extraction from the fresh frozen samples was performed using the QIAamp Stool Mini Kit

(Qiagen, Germany) according to the manufacturer's instructions. This kit is designed for rapid purification of total DNA from up to 220 mg stool and is suitable for both fresh and frozen samples. Briefly, extraction of DNA was done by lysis of samples in the fecal lysis buffer. One Inhibit EX tablet was added to each sample and vortexed immediately continuously for 1 min until the tablet was completely suspended. The suspension was then incubated for 5 min at room temperature to allow inhibitors to adsorb to the Inhibit EX matrix. Purification of extracted DNA was done on QIAamp spin columns. DNA was then eluted in 50 µl buffer (Qiagen) and stored at -20°C till use.

**Amplification of extracted genomic DNA (Copro n-PCR):** For the molecular characterization of *Cryptosporidium spp.*, amplification of the extracted genomic DNA was performed using nPCR analysis of cowp gene. Amplification was done according to the manufacturer's instructions. Two sets of primers were used such that first set was used to produce an amplicon template for the nested reaction. The second set of primers was used to anneal internally within the previously obtained amplicon increasing the specificity of detection.<sup>(8)</sup>

The details of the target gene, primers sequences, and amplicon size are shown in table (1).

**Table (1)** Primers used in PCR for the target *COWP* gene and its sequence<sup>(8)</sup>.

| Primers   | Sequence   | Product size | Annealing temperature |
|-----------|--|--------------|-----------------------|
| Primary   | 1) Forward primer (COWP-F):<br>CCGCTTCTCAACAACCATCTTGTCTC-3'   | 5'           | 769 bp<br>63oC        |
|           | 2) Reverse primer (COWP-R):<br>CGCACCTGTTCCCACTCAATGTAAACCC-3' | 5'           |                       |
| Secondary | 1) Forward primer (Cry-15):<br>GTAGATAATGGAAGAGATTGTG-3'       | 5'           | 553 bp<br>54oC        |
|           | 2) Reverse primer (Cry-9):<br>GGACTGAAATACAGGCATTATCTTG-3      | 5'           |                       |

**Restriction fragment length polymorphism (RFLP):** The amplified products of nPCR of positive samples were digested using restriction enzymes according to manufacture instructions. The DNA sample was digested by *RsaI* restriction enzyme (Thermo Scientific #FD1124) and the resulting restriction fragments were separated according to their lengths by gel electrophoresis. Restriction assays were performed in 30 µL volume with 2 units of restriction enzyme and 5 µL of PCR product per reaction. Mixtures were incubated in a heating block. Digestion products were visualized under UV light in 2% agarose gel electrophoresis after ethidium bromide staining. Digested PCR product with these enzymes resulted in a distinct band pattern for the human and bovine genotypes. The amplicon size of the digested products for *C. hominis* was distinct bands at: 106 bp, 125 bp, 285 bp.

**DNA sequencing:** PCR products of the cowp gene were purified using Illustra GFX PCR DNA and Gel band Purification Kit – GE Healthcare and cycle sequencing using ABI PRISM Big Dye Terminator Cycle Sequencing Ready Reaction Kit

and using Centri-Sep columns (Princeton separations) (cat no. CS-901) for dye terminator removal.

**Statistical analysis:** results were gathered, organized and tabulated in an Excel 2013 spreadsheet. Data were analyzed using IBM SPSS Statistics for Windows version 27.0. Quantitative data were expressed as mean ± standard deviation, median, and range. Qualitative data were expressed as number and percentage. The data were tested for normality using the Shapiro-Wilk test. The nonparametric kruskal-wallis test or Mann–Whitney test was used for data which was not normally distributed. Chi-square ( $\chi^2$ ) test was used for comparison regarding qualitative variables as appropriate. A 5% level was chosen as a level of significance in all statistical tests used in the study.

**Ethical approval:** The research protocol was approved by the Medical Research Ethics Committee Faculty of Medicine - Sohag University (OHRP #: IRB00013006) under IRB registration number (Soh-Med-22-01-12) as it complies


with the 1964 Helsinki declaration. This study was registered at Clinicaltrials. Gov (ID: NCT05208970) [<http://clinicaltrials.gov/ct2/show/record/NCT052>

08970]). Verbal consent from participants or from parents or guardians of children in the study was obtained after a clear explanation of the study objectives.

## Results

Out of the 245 study participants, the age of the study individuals ranged from 2.5 to 90 years with a mean and standard deviation of  $23.6 \pm 20.9$

**Microscopic examination:** Using MZN-stained fecal smear, 49/245 samples (20%), were positive for *Cryptosporidium* oocysts. Figure (1)



**Figure (1)** *Cryptosporidium* oocysts stained by MZN stain (1000X).

**Prevalence of *Cryptosporidium* infections among different Sohag Governorate Districts:** The analysis of *Cryptosporidium* prevalence across the districts of Sohag Governorate reveals variability in infection rates but there was no statistical significance ( $p$ -value= 0.09). the data highlighted Akhmim, Sohag and El Maragha as districts of particular concern, exhibiting the highest prevalence at 18 (7.3%), 9 (3.7%) and 7 (2.9%) respectively. Table (2)

**Table (2)** Prevalence of *Cryptosporidium* infections in Sohag Governorate Districts

| Sohag Governorate Districts | <i>Cryptosporidium</i> diagnosed by MZN |            |       | p-value |
|-----------------------------|---|------------|-------|---------|
|                             | Positive                                | Negative   | Total |         |
| Akhmim                      | 18 (7.3%)                               | 40 (16.3%) | 58    | 0.09*   |
| Sohag                       | 9 (3.7%)                                | 66 (26.9%) | 75    |         |
| El Maragha                  | 7 (2.9%)                                | 8 (3.3%)   | 15    |         |
| Girga                       | 4 (1.6%)                                | 18 (7.3%)  | 22    |         |
| Tahta                       | 2 (0.8%)                                | 13 (5.3%)  | 15    |         |
| Saqultah                    | 2 (0.8%)                                | 11 (4.5%)  | 13    |         |
| El Munsha                   | 2 (0.8%)                                | 15 (6.1%)  | 17    |         |
| El Balyana                  | 2 (0.8%)                                | 6 (2.4%)   | 8     |         |
| Juhaynah                    | 1 (0.4%)                                | 5 (2%)     | 6     |         |
| Dar al-Salam                | 1 (0.4%)                                | 10 (4.1%)  | 11    |         |
| Tima                        | 1 (0.4%)                                | 4 (1.6%)   | 5     |         |
| Total                       | 49 (20%)                                | 196 (80%)  | 245   |         |

Data presented as n and percentage with (%). kruskal-wallis test:  $P$  value  $\leq 0.05$  is significant\*.

***Cryptosporidium* Infection in Various Patient Categories:** The study found significant differences in *Cryptosporidium* infection rates among patient categories, with a  $p$ -value of 0.002 indicating statistical significance. Asymptomatic immunocompetent individuals had a 6.9% infection rate, while symptomatic immunocompetent patients experienced a higher rate of 15.6%. Patients with chronic diseases exhibited the highest infection rate at 37.8%, particularly those with diabetes mellitus (55.6%) and chronic kidney disease

(43.8%). Among immunocompromised patients, including those with hematological malignancies and cancers undergoing chemotherapy, the infection rate was 31.3%. Table (3,4,5)

**Table (3) Prevalence of *Cryptosporidium* Infection in Various Patient Categories**

| patient categories            |                           | <i>Cryptosporidium</i> diagnosed by MZN |          | Total      | p-value |
|-------------------------------|---------------------------|---|----------|------------|---------|
|                               |                           | Negative                                | Positive |            |         |
| Asymptomatic immunocompetent  | Count                     | 27                                      | 2        | 29         | 0.002*  |
|                               | % within patient_category | 93.1%                                   | 6.9%     | 100.0%     |         |
|                               | % of Total                | 11%                                     | 0.8%     | 11.8%      |         |
| Symptomatic immunocompetent   | Count                     | 124                                     | 23       | 147        |         |
|                               | % within patient_category | 84.4%                                   | 15.6%    | 100.0%     |         |
|                               | % of Total                | 50.6%                                   | 9.4%     | 60 %       |         |
| Patients with Chronic disease | Count                     | 23                                      | 14       | 37         |         |
|                               | % within patient_category | 62.2%                                   | 37.8%    | 100.0%     |         |
|                               | % of Total                | 9.4%                                    | 5.7%     | 15.1%      |         |
| Immunocompromised patients    | Count                     | 22                                      | 10       | 32         |         |
|                               | % within patient_category | 68.8%                                   | 31.3%    | 100.0%     |         |
|                               | % of Total                | 9 %                                     | 4.1%     | 13.1%      |         |
| <b>Total</b>                  | Count                     | 196 (80%)                               | 49 (20%) | 245 (100%) |         |

Data presented as n and percentage with (%). kruskal-wallis test: P value  $\leq 0.05$  is significant\*.

**Table (4) Prevalence of *Cryptosporidium* among Patients with Chronic Diseases**

| Patients with Chronic Diseases | Positive No. (%) | Negative No. (%) | Total No. (%) |
|--------------------------------|------------------|------------------|---------------|
| CKD                            | 7 (43.8%)        | 9 (56.3%)        | 16 (100%)     |
| DM                             | 5 (55.6%)        | 4 (44.4%)        | 9 (100%)      |
| Hepatic diseases               | 0 (0.00%)        | 3 (100%)         | 3 (100%)      |
| Chronic Pulmonary diseases     | 1 (50%)          | 1 (50%)          | 2 (100%)      |
| Cardiac diseases               | 1 (33.3%)        | 2 (75%)          | 3 (100%)      |
| Rheumatic diseases             | 0 (0.00%)        | 4 (100%)         | 4 (100%)      |
| Total                          | 14 (37.8%)       | 23 (62.2%)       | 37 (100%)     |

Data presented as n and percentage with (%).

**Table (5) Prevalence of *Cryptosporidium* among immunocompromised patients**

| Immunocompromised patients     | Positive No. (%) | Negative No. (%) | Total No. (%) |
|--------------------------------|------------------|------------------|---------------|
| Haematological malignancies    | 7 (33.3%)        | 14 (66.7%)       | 21 (100%)     |
| colorectal cancer              | 2 (25%)          | 6 (75%)          | 8 (100%)      |
| Hepatocellular carcinoma (HCC) | 1 (33.3%)        | 2 (66.7%)        | 3 (100%)      |
| Total                          | 10 (31.3%)       | 22 (68.7%)       | 32 (100%)     |

Data presented as n and percentage with (%).

**Relationship between *Cryptosporidium* infection and different risk factors:** The analysis revealed statistically significant associations between *Cryptosporidium* infections and various factors, with a p-value of 0.05 for age, indicating a significant relationship; children aged 2 to 12 years (8.2%) tested positive, while adolescents (2%), young adults (1.6%), middle-aged individuals (3.3%), and older adults (4.9%) were infected. The p-value for residence was 0.018, suggesting that living in rural areas correlates with higher infection rates. Gender did not show a statistically significant relationship. Although a higher prevalence was observed among individuals using tap water 13.5%, statistical analysis did not reveal a significant relationship between water source and infection rates, nor did contact with animals show any significant association. Table (6)


**Table (6) analysis of different risk factors for *Cryptosporidium* infections among study individuals.**

| Variables      | Categories             | <i>Cryptosporidium</i> diagnosed by MZN |             | p-value |
|----------------|------------------------|---|-------------|---------|
|                |                        | Present                                 | Absent      |         |
| Age            | Children: 2 to 12      | 20 (8.2%)                               | 104 (42.4%) | 0.05*   |
|                | Adolescence: 13 to 19  | 5 (2%)                                  | 22 (9 %)    |         |
|                | Young Adults: 20 to 35 | 4 (1.6%)                                | 22 (9%)     |         |
|                | Middle age: 36 to 55   | 8 (3.3%)                                | 30 (12.2%)  |         |
|                | Old age: $\geq 56$     | 12 (4.9%)                               | 18 (7.3%)   |         |
| Gender         | Male                   | 26 (10.6%)                              | 93 (38%)    | 0.482   |
|                | Female                 | 23 (9.4%)                               | 103 (42%)   |         |
| Residence      | Rural                  | 34 (13.9%)                              | 99 (40.4%)  | 0.018*  |
|                | Urban                  | 15 (6.1%)                               | 97 (39.6%)  |         |
| Animal contact | Yes                    | 17 (7.6%)                               | 81 (36.3%)  | 0.227   |
|                | No                     | 30 (13.5%)                              | 95 (42.6%)  |         |
| Drinking water | Filter                 | 15 (6.7%)                               | 56 (25.1%)  | 0.753   |
|                | Tap                    | 30 (13.5%)                              | 116 (52%)   |         |
|                | Underground            | 2 (0.9%)                                | 4 (1.8%)    |         |

Data presented as n and percentage with (%). Chi-square ( $\chi^2$ ) test:  $P$  value  $\leq 0.05$  is significant\*.

**Nested-PCR amplification of cowp gene:** DNA was extracted from 49 stool samples that were all positive for *Cryptosporidium* by microscopic examination, using cowp gene, 2/49 stool (4%), samples were successfully amplified at 553 bp.

**Molecular characterization of *Cryptosporidium* by n-PCR-RFLP:** Results proved that *Cryptosporidium hominis* genotype I. was the only detected species. No other *Cryptosporidium* spp. was detected. Figure (2)



**Figure (2)** Agarose gel electrophoresis for COWP nPCR-RFLP products after digestion with RasI endonuclease. Lane L100: 100 bp DNA marker ladder. Lanes 1: *Cryptosporidium hominis* genotype I digestion products at 34, 106, 125 and 285 bp. Lanes 2-4: negative samples.

**Sequencing Analysis:** The sequencing of n-PCR products corresponding to the COWP protein gene confirmed the presence of *Cryptosporidium hominis* species. The sequence obtained was as follows:

```
(TTGCATTCACTATGCCTGAAAAATCATGTCCCCAGGATTCGTCTTTTCTGGAAAACAATGTGT
TCAATCAGACACAGCTCCTCCTAATCCAGAATGTCCTCCAGGTAATACTGGAAAATGGCAC
ATGTA AATTAATTCAACAAATTGATACCGTTTGTCTTCTGGTTTTGTTGAAGAAGGAAATAGA
TGTGTTCAATATCTCCCTGCAAACAAAATCTGTCCTCCTGGATTCAATTTGTCAGGACAACAAT
GTATGGCACCAGAATCAGCTGAATTAGAATCGACATGCCACCTAATTCAATATTTGAAAATG
GAAAATGTAAAGTGATTA AAAATATTGATATGGTCTGCCCACCAGGATATACAGATTCAGGAG
ATGATTGTGTACTATATGTAGCTCCTGCAAAGGAATGCCACCAAATTTTCATTTTACAAGGCCT
CCAGTGTATTCAA ACTAGTTCTGCTCCA ACTCAACCTGTCTGCCCTCCAGGTACAGTATTACAA
GATAATGCCTGTATTTCAGTCCAAGCAATC)
```

## Discussion

The study determined the prevalence and species of *Cryptosporidium* in Sohag Governorate and identified associated risk factors, revealing that 20% of the total cases (49/245) were infected with *Cryptosporidium* using the MZN staining method. Among asymptomatic immunocompetent individuals, the prevalence was 6.9% (2/29), consistent with **El-Hady et al. (2017)**,<sup>(9)</sup> who reported 10% in a similar group from Sohag.

**Elsawey et al. (2020)**<sup>(10)</sup> found a 4% prevalence among asymptomatic immunocompetent individuals in Mansoura, while **Abd Ellah et al. (2024)**<sup>(11)</sup> reported a lower rate of 3% in Sohag. In contrast, **Abdel-Hafeez et al. (2012)**<sup>(12)</sup> found a 42.2% prevalence among immunocompetent children in Minia, and **Ibrahim et al. (2016)**<sup>(13)</sup> reported 15.7% in asymptomatic immunocompetent patients from Beni-Suef.

The prevalence of *Cryptosporidium spp.* among symptomatic immunocompetent individuals with diarrhea, abdominal pain, low weight, or fever was 15.6% (23/147). This aligned with **Mohammad et al. (2021)**,<sup>(14)</sup> who reported a 27.8% infection rate among children with diarrhea in Sharkya Governorate, while **Yousof et al. (2023)**<sup>(15)</sup> found 10.5% in preschool children with diarrhea in Cairo, and **Mohamed & Masoud (2023)**<sup>(16)</sup> reported 17.1% in symptomatic patients. **Abd Ellah et al. (2024)**<sup>(11)</sup> noted a 20% prevalence in symptomatic patients from Sohag Governorate.

In contrast, **Helmy et al. (2013)**<sup>(17)</sup> reported a prevalence of 49.1% among children with diarrhea in Ismailia, and **Shalaby & Shalaby (2015)**<sup>(18)</sup> found 30.8% in school children with diarrhea in Mansoura. Additionally, **El-Nadi et al. (2017)**<sup>(19)</sup> reported a 31.5% prevalence among elementary school children aged 6 to 12 years in Sohag, while **Dyab et al. (2018)**<sup>(20)</sup> found 40% among diarrheic children in the same region.

The study found a 37.8% (14/37) prevalence of *Cryptosporidium spp.* among patients with chronic diseases, indicating a significant association between chronic health conditions and this parasitic infection, with the highest prevalence observed in diabetes mellitus patients at 55.6% (5/9) and chronic kidney disease patients at 43.8% (7/16). This increased susceptibility can be attributed to acquired immunodeficiency from

uremia impairing immune function,<sup>(21)</sup> as well as alterations in immune cell function due to diabetes that compromise defense mechanisms against pathogens.<sup>(22)</sup> Chronic inflammation associated with these diseases can lead to immune dysregulation and increased levels of pro-inflammatory cytokines like IL-6 and TNF- $\alpha$ , linked to both chronic diseases and heightened infection risk.<sup>(23)</sup>

These findings aligned with previous research highlighting the association between chronic illnesses and increased susceptibility to *Cryptosporidium spp.* infections; for instance, **El-Kady et al. (2018)**<sup>(24)</sup> reported a 40% prevalence among CKD patients receiving hemodialysis in Qena Governorate, while **Ahmed et al. (2022)**<sup>(25)</sup> found a 35% prevalence in CKD patients from Sohag. **Morsy et al. (2024)**<sup>(26)</sup> reported a 29.5% prevalence in diabetic individuals from Kafrelsheikh Governorate, and **Mohamed et al. (2024)**<sup>(27)</sup> noted a 36% prevalence in diabetic children from Minia Governorate.

Among immunocompromised patients—including those with hematological malignancies, colorectal cancer, and hepatocellular carcinoma receiving chemotherapy—the prevalence of *Cryptosporidium spp.* was found to be 31.3% (10/32), with rates of 33.3% (7/21) for hematological malignancies, 25% (2/8) for colorectal cancer, and 33.3% (1/3) for hepatocellular carcinoma. Hematological malignancies can significantly impair the immune system due to the disease or chemotherapy, creating conditions favorable for opportunistic infections like *Cryptosporidium spp.*<sup>(28)</sup>

Epidemiological evidence also links *Cryptosporidium* infections to gastrointestinal cancers, particularly colorectal and hepatocellular carcinoma, where chronic infections may promote tumor growth in immunocompromised individuals.<sup>(29)</sup>

These findings are consistent with studies indicating notable prevalence rates of *Cryptosporidium spp.* infections among patients with hematological malignancies and gastrointestinal cancers; **Mohammad et al. (2021)**<sup>(30)</sup> reported a 29.7% prevalence among children with hematological malignancies in Sharqiyah Governorate, while **Seleem et al. (2024)**<sup>(31)</sup> found a 14% prevalence in intestinal cancer patients from Sohag Governorate. **Zhang et al. (2020)**<sup>(32)</sup> reported a 13.3%

infection rate among gastrointestinal cancer patients, including 17.24% for colorectal cancer and 14.29% for liver cancer.

In contrast, **Abdel-Hafeez et al. (2012)**<sup>(12)</sup> reported a higher prevalence of *Cryptosporidium* spp., at 60%, among immunosuppressed children in Minia Governorate; **El-Hady et al. (2017)**<sup>(9)</sup> found a prevalence of 45% among children undergoing chemotherapy in Sohag Governorate, while **Mohamed et al. (2020)**<sup>(33)</sup> also reported a 45% infection rate among immunocompromised patients in Sohag. This contrasts sharply with a study conducted in Saudi Arabia that revealed a *Cryptosporidium* infection rate of 70.3% among patients with various malignancies—including rates of 50% for both colon and liver cancer and an alarming 100% for lymphoma.<sup>(34)</sup>

The study revealed statistical significance between *Cryptosporidium* infection and patient categories with a p-value of 0.002.

Parasitic infections are a significant public health concern, leading to considerable morbidity and mortality. The COVID-19 pandemic may have contributed to a decline in the prevalence of *Cryptosporidium* spp. infections across various patient categories, as evidenced by studies examining prevalence changes before and after the pandemic.<sup>(35)</sup>

A study in Saudi Arabia found that quarantine measures led to a reduction in parasitic infections, with the prevalence of *Cryptosporidium* dropping from 2.5% pre-COVID to 1.3% during the pandemic.<sup>(36)</sup> Research in New Zealand indicated that *C. hominis* disappeared from early 2020 to early 2021 due to lockdown measures, while *C. parvum* maintained its typical transmission patterns.<sup>(37)</sup>

Similarly, a study in England and Wales reported a 97.5% reduction in *C. hominis* and a 49% decrease in *C. parvum* cases following public health measures that limited social interactions and travel.<sup>(38)</sup> In Scotland, there was a significant drop in *C. hominis* cases during the pandemic, with only five cases reported compared to previous years, although a small peak in *C. parvum* cases was noted in November 2020.<sup>(5)</sup>

The COVID-19 pandemic has led to significant changes in hygiene practices, which may have inadvertently reduced the prevalence of intestinal parasitic infections including cryptosporidiosis. Public health campaigns promoted handwashing, the use of hand sanitizers, and general cleanliness

as measures against COVID-19.<sup>(39)</sup> Lockdowns minimized human interactions, reducing opportunities for the spread of intestinal parasites often transmitted through contaminated food or water.<sup>(40)</sup>

Additionally, improvements in sanitation and waste management were observed, with increased public awareness and investment in sanitation infrastructure leading to decreased contamination of water sources and food supplies.<sup>(41)</sup> Antiparasitic medications such as Metronidazole, Nitazoxanide, and Ivermectin were also incorporated into COVID-19 treatment protocols,<sup>(42-44)</sup> The sustained focus on hygiene and sanitation may yield long-term effects on the prevalence of intestinal parasites.<sup>(45)</sup>

This study was the first conducted in the Sohag Governorate to detect *Cryptosporidium* species which was *Cryptosporidium hominis* genotype I; using n-PCR\RFLP and sequencing techniques. *C. hominis* is one of the two most common species of *Cryptosporidium* that infect humans, responsible for more than 90% of cases. *C. hominis* is predominantly anthroponotic, meaning it is primarily transmitted from human to human. This genotype is rarely associated with zoonotic transmission.<sup>(46)</sup>

Studies in various Egyptian governorates show that *Cryptosporidium hominis* was the predominant species. In Ismailia, 60.5% of cases were *C. hominis*, with 38.2% *C. parvum*<sup>(17)</sup>. In Cairo, **El-Badry et al. (2015)**<sup>(47)</sup> reported 95.8% for *C. hominis* and 3.0% for *C. parvum*. **Ibrahim et al. (2016)**<sup>(13)</sup> confirmed *C. hominis* as the main species in Beni-Suef, highlighting both anthroponotic and zoonotic transmission. **Naguib et al. (2018)**<sup>(48)</sup> found a notable prevalence of *C. hominis* in El-Dakahlia, El-Gharbia, and Damietta. **Elsawey et al. (2020)**<sup>(10)</sup> also reported that *C. hominis* was the most prevalent species 52.5% among cryptosporidiosis-positive children in Mansoura Governorate. In Cairo Governorate, **Wahed et al. (2021)**<sup>(49)</sup> found a prevalence of 19% for *C. hominis* in children with acute gastroenteritis. **Amin et al. (2021)**<sup>(50)</sup> reported that among elderly patients over 60, *C. hominis* made up 80% of cases. In Sharkya Governorate, **Mohammad et al. (2021)**<sup>(14)</sup> showed *C. hominis* in 65.2% of diarrhea cases and 62.2% in children with cancer. **Ghallab et al. (2022)**<sup>(51)</sup> noted a higher prevalence of *C. hominis* in Kafr El-Sheikh



among both immunocompetent (60%) and immunocompromised (82.6%) patients.

This finding contrasted with a study in Alexandria Governorate, which identified *C. parvum* in children with malignancies.<sup>(52)</sup> Additionally, research in Fayoum Governorate found a predominance of *C. parvum* at 72.7%, indicating a higher prevalence of zoonotic transmission, particularly in farming areas.<sup>(16)</sup> Similarly, a study in Baghdad Governorate, Iraq, reported a human infection rate of 47.33%, with 46% attributed to *C. parvum* and only 1.33% to *C. hominis*.<sup>(53)</sup>

The observed discrepancy in this study between staining and molecular diagnosis for *Cryptosporidium* may be attributed to either the presence of false negative results of PCR or false-positive results in the staining method.

The detection rate of *Cryptosporidium* oocysts by PCR can be significantly affected by various factors, leading to false negatives. A low count of oocysts, around 150 per sample, can result in insufficient DNA for PCR.<sup>(54)</sup> In a study, 8.2% of samples that were positive by microscopy tested negative by PCR due to low oocyst counts.<sup>(55)</sup>

Additionally, substances like bilirubin and bile salts can inhibit PCR performance, causing false negatives even when oocysts are present.<sup>(56)</sup>

Improper handling and processing can also lead to DNA degradation, especially in small samples.<sup>(57)</sup>

Carbol fuchsin stains can target *Cryptosporidium* oocysts but may also stain other organisms, such as yeasts and bacteria, leading to potential misinterpretation during microscopic examination.<sup>(58)</sup> **Chen et al.(2023)**<sup>(59)</sup> reported a prevalence of 3.0% for *Cryptosporidium* using staining, compared to 2.0% with molecular methods, indicating that the staining technique may yield unreliable results.

While PCR can have a reported specificity of up to 100%, stool samples with oocyst-like bodies that do not produce specific PCR amplification may still be deemed negative, although they cannot be entirely excluded.<sup>(60)</sup> The challenges in achieving accurate diagnoses are further highlighted by the specificity and sensitivity of methods like ELISA and acid-fast staining,<sup>(61)</sup> underscoring the complexities in diagnostic methodologies.

In the present study, we found a statistically significant association between *Cryptosporidium* infection and age (p-value of 0.05), with an 8.2% prevalence in children aged 2 to 12 years (20/245

cases). This aligned with a study in the Cairo Governorate, which reported a 14.5% prevalence in children versus 5% in adults.<sup>(47)</sup> A systematic review by **Dong et al. (2020)**<sup>(62)</sup> confirmed that children are more susceptible, with the highest prevalence among school children.

**Elsawey et al. (2020)**<sup>(10)</sup> attributed this to children's immature intestinal immunity, unhygienic behaviors, and poor handwashing. Among elderly patients over 56 years old, we found a 4.9% prevalence of *Cryptosporidium* spp., which is consistent with **Amin et al. (2021)**,<sup>(50)</sup> who reported a 3.7% prevalence in those over 60 years.

In the present study, we found statistical significance between *Cryptosporidium* infection and residence, with p-values of 0.018. The findings indicated that the prevalence of *Cryptosporidium* was higher among participants from rural areas (13.9%) compared to those from urban areas (6.1%). This may be due to poor hygiene, low socioeconomic conditions, possibly contaminated water sources, occupational risk, sanitary conditions, and higher population densities with a risk of person-to-person transmission as well.<sup>(63)</sup>

This finding agreed with a study by **Dyab et al. (2018)**<sup>(20)</sup> in Sohag Governorate found that infection rates were higher in rural areas compared to urban areas (60% vs. 20%), with a significant p-value of 0.001. Similarly, **Ghallab et al. (2022)**<sup>(51)</sup> reported in Kafr El-Sheikh Governorate a significant relationship between residence and infection rates, also indicating a higher prevalence in rural areas (p-value < 0.005).

In contrast, A study in El-Dakahlia, El-Gharbia, and Damietta found similar prevalence rates of *Cryptosporidium* spp. among children in rural (1.5%) and urban (1.2%) areas, with a p-value of 0.76 indicating no significant difference.<sup>(48)</sup> A study in Cairo Governorate on *Cryptosporidium* spp. infections in elderly Egyptians found that 70% of positive samples were from rural areas and 30% from urban areas. However, this difference was not statistically significant, indicating no strong correlation between residence type and infection rates.<sup>(50)</sup>

Regarding drinking water sources, the present study found that 13.5% of positive cases consumed tap water, which is partially impure, compared to only 6.7% who reported drinking filtered water, this may be explained by the fact

that the routes of infection in this locality may be waterborne; however, there was no statistically significant association between cryptosporidiosis and the water source, as indicated by a p-value of 0.753.

It was consistent with a study investigating the epidemiology of *Cryptosporidium spp.* in diarrheic immunocompetent patients in Beni-Suef Governorate, which found that although tap water was associated with higher infection rates compared to filtered water (22.7% and 10.7%, respectively), there was no statistically significant association (p-value = 0.1).<sup>(57)</sup>

Similarly, in a study investigating cryptosporidiosis among outpatients with diarrhea in El-Fayoum Governorate, the highest rate (90.6%) was detected among tap water users without statistically significant association (p-value=0.24).<sup>(16)</sup> In contrast, a study by **Dwi et al., (2023)**<sup>(64)</sup> found that one person was infected with *Cryptosporidium* despite most research subjects using unhealthy healthy water as a drinking water source.

Regarding contact with animals, in the present study, we observed no significant association between cryptosporidiosis and contact with animals, as indicated by (p-value=0.227). This finding underscores the importance of anthroponotic transmission in the spread of *Cryptosporidium spp.*

This finding aligned with **Xiao and Feng (2008)**,<sup>(65)</sup> who noted that many infections from zoonotic species may actually stem from human-to-human transmission rather than animal-to-human. **Boughattas et al. (2019)**<sup>(66)</sup> found no significant link between cryptosporidiosis and animal contact (p-value=0.092), suggesting that the role of animals might be overestimated. **Krumkamp et al. (2020)**<sup>(67)</sup> observed that transmission among infected children primarily occurred between household members and neighbors, indicating a higher prevalence of human-to-human transmission. Similarly, **Mohammad et al. (2021)**<sup>(14)</sup> reported no correlation with animal contact (p-value=0.6), underscoring the need to investigate alternative transmission routes. Conversely, **El-Sherbini and Mohammad (2006)**<sup>(68)</sup> identified a statistically significant association between farmers and their farm animals infected with *C. parvum*, indicating a zoonotic potential for the infection (p-value < 0.01).

Furthermore, **Izadi et al. (2014)**<sup>(69)</sup> reported that cryptosporidiosis poses an occupational risk for

individuals in contact with cattle, providing strong evidence of zoonotic transmission from calves to humans (p-value < 0.0001). Additionally, a study by **Mohamed and Masoud (2023)**<sup>(16)</sup> found a significant infection rate among patients having indoor animals (p-value=0.001).

The predominance of anthroponotic *Cryptosporidium* strain, coupled with the lack of association between *Cryptosporidium* prevalence and animal contact in the present study population, suggests that population dynamics significantly influence the transmission patterns of *Cryptosporidium* in Sohag. Notably, *C. hominis* presents considerable public health challenges, particularly in regions with limited access to clean water and sanitation facilities.

Regarding gender, the analysis of gender differences in the study revealed that the infection rate among males was slightly higher than that of females, with 26 cases (10.6%) in males compared to 23 cases (9.4%) in females. However, this difference was not statistically significant, as indicated by a p-value of 0.48.

This finding aligned with **Boughattas et al. (2019)**,<sup>(66)</sup> which showed no significant gender difference in *Cryptosporidium spp.* prevalence among immigrants in Qatar (males 4.4%, females 4.7%; p-value 0.83). Similarly, **Khan et al. (2019)**<sup>(70)</sup> reported a p-value of 0.38 when comparing infection rates by gender, indicating no significant difference. Additionally, **Mohammad et al. (2021)**<sup>(14)</sup> found no significant relationship between gender and infection rates among Egyptian children with cancer (p-value 0.7), despite a higher prevalence in males. In contrast, **Dyab et al. (2018)**<sup>(20)</sup> who found the rate of *Cryptosporidium* infection among male children was significantly higher than the rate among females (p-value = 0.001). Additionally, **Sinyangwe et al. (2020)**<sup>(71)</sup> investigated factors associated with *Cryptosporidium* infection among HIV-positive patients in Zambia and found that males were 2.5 times more likely to be infected than females, with a statistically significant p-value of 0.02.

### Limitations

The study on *Cryptosporidium* prevalence in the Sohag Governorate has some limitations: the first was the low sample size which may restrict the findings' generalizability as the study was self-funded, Fluctuations in the dollar exchange rate and the broader economic conditions of the

country affect the cost of materials and methods used in the study and due to the limited facilities.

## Conclusion

The prevalence of *Cryptosporidium* in Sohag Governorate was 20% with significant associations in children aged 2-12 years and in rural areas. significant association with patient categories, especially immunocompromised and chronic disease patients. The identification of *C. hominis* indicates anthroponotic transmission. the relatively low prevalence of *Cryptosporidium* underscores the positive impact of public health measures implemented during and after COVID-19 pandemic on reducing parasitic infections.

## Recommendations

Future studies should involve larger sample sizes for better generalizability and detailed subgroup analyses, focusing on age groups and clinical statuses. The study recommend researching environmental factors like water quality and sanitation practices to assess their impact on *Cryptosporidium* transmission. Continued monitoring of *Cryptosporidium* prevalence post-COVID-19 is also essential to understand the long-term effects of pandemic-related public health measures on intestinal parasitic infections.

**Acknowledgements:** The authors would like to thank all the participating patients, and we hope that they get better soon.

## References

1. Khalil, I. A., Troeger, C., Rao, P. C., Blacker, B. F., Brown, A., Brewer, T. G., Colombara, D. V., De Hostos, E. L., Engmann, C., Guerrant, R. L., Haque, R., Houpt, E. R., Kang, G., Korpe, P. S., Kotloff, K. L., Lima, A. A. M., Petri, W. A., Platts-Mills, J. A., Shoultz, D. A., ... Mokdad, A. H., Morbidity, mortality, and long-term consequences associated with diarrhoea from *Cryptosporidium* infection in children younger than 5 years: a meta-analysis study. *The Lancet Global Health*. 2018; 6(7), e758–e768. [https://doi.org/10.1016/S2214-109X\(18\)30283-3](https://doi.org/10.1016/S2214-109X(18)30283-3)
2. Hassan, E. M., Örmeci, B., DeRosa, M. C., Dixon, B. R., Sattar, S. A., & Iqbal, A., A review of *Cryptosporidium* spp. And their detection in water. *Water Science and Technology*. 2021; 83(1), 1–25. <https://doi.org/10.2166/wst.2020.515>
3. Holubová, N., Zikmundová, V., Limpouchová, Z., Sak, B., Konečný, R., Hlásková, L., Rajský, D., Kopacz, Z., McEvoy, J., & Kváč, M., *Cryptosporidium proventriculi* spp. n. (Apicomplexa: Cryptosporidiidae) in Psittaciformes birds. *European Journal of Protistology*. 2019; 69, 70–87. <https://doi.org/10.1016/j.ejop.2019.03.001>
4. Gerace, E., Presti, V., & Biondo, C., *Cryptosporidium* infection: Epidemiology, pathogenesis, and differential diagnosis. *European Journal of Microbiology and Immunology*. 2019; 9(4), 119–123. <https://doi.org/10.1556/1886.2019.00019>
5. Bacchetti, R., Connelly, L., Browning, L., & Alexander, C. L., Changing Molecular Profiles of Human *Cryptosporidiosis* Cases in Scotland as a Result of the Coronavirus Disease, COVID-19 Pandemic. *British Journal of Biomedical Science*. 2023; 80. <https://doi.org/10.3389/bjbs.2023.11462>
6. Ahmed, S. A., & Karanis, P., Comparison of current methods used to detect *Cryptosporidium* oocysts in stools. *International Journal of Hygiene and Environmental Health*. 2018; 221(5), 743–763. <https://doi.org/10.1016/j.ijheh.2018.04.006>
7. Garcia, L. S. (2016). *Diagnostic Medical Parasitology*. 2016. <https://doi.org/10.1128/9781555819002>
8. Pedraza-Díaz, S., Amar, C., Nichols, G. L., & McLaughlin, J., Nested polymerase chain reaction for amplification of the *Cryptosporidium* oocyst wall protein gene. *Emerging Infectious Diseases*. 2001; 7(1), 49–56. <https://doi.org/10.3201/eid0701.700049>
9. El-Hady, A., Sammer Ahmed, N., Ahmed, M., Taha, A., Mohamed, N., El-Kareem, A., & Bakheet, R. A., Intestinal Parasites in Children Receiving Chemotherapy. *Journal of the Egyptian Society of Parasitology*. 2017; 47(2), 375–380. <https://doi.org/10.21608/jesp.2017.77790>
10. Elsawey, A. M., Elgendy, S. H., Abdel-Magied, S. A., Mosaad, Y., & Nabih, N., Prevalence of *Cryptosporidium* species among immunocompetent and immunocompromised

- Egyptian children: comparative study. *Parasitologists United Journal*. 2020; 13(2), 114–120. <https://doi.org/10.21608/puj.2020.27731.1068>
11. Abd Ellah, A. K., Ahmed, A. M., Ahmed, N., & Al-Amir, H. M., Intestinal Parasitic Infections in Patients with Irritable Bowel Syndrome in Sohag, Egypt. *Journal of the Egyptian Society of Parasitology*. 2024; 54(2), 277–282. <https://doi.org/10.21608/jesp.2024.373528>
  12. Abdel-Hafeez, E. H., Ahmad, A. K., Ali, B. A., & Moslam, F. A., Opportunistic parasites among immunosuppressed children in Minia District, Egypt. *Korean Journal of Parasitology*. 2012; 50(1), 57–62. <https://doi.org/10.3347/kjp.2012.50.1.57>
  13. Ibrahim, M. A., Abdel-Ghany, A. E., Abdel-Latef, G. K., Abdel-Aziz, S. A., & Aboelhadid, S. M., Epidemiology and public health significance of *Cryptosporidium* isolated from cattle, buffaloes, and humans in Egypt. *Parasitology Research*. 2016; 115(6), 2439–2448. <https://doi.org/10.1007/s00436-016-4996-3>
  14. Mohammad, S. M., Ali, M. S., Abdel-Rahman, S. A., Moustafa, R. A., & Sarhan, M. H., Genotyping of *Cryptosporidium* species in children suffering from diarrhea in Sharkyia Governorate, Egypt. *Journal of Infection in Developing Countries*. 2021; 15(10), 1539–1546. <https://doi.org/10.3855/jidc.14367>
  15. Yousof, H.-A., Abdalgeleel, S., & El-sayed, S., Screening for the Burden of Enteric Parasitic Infections Among Egyptian Pre-Schoolers with Gastrointestinal Manifestations: A Cross-Sectional Study. *Egyptian Academic Journal of Biological Sciences*. 2023; 15(1), 1–10. <https://doi.org/10.21608/eajbse.2023.286095>
  16. Mohamed, F., & Masoud, M., Cryptosporidiosis Among Outpatients with Diarrhea In El Fayoum General Hospital Egypt: Diagnosis and Risks. *Journal of the Egyptian Society of Parasitology*. 2023; 53(1), 57–62. <https://doi.org/10.21608/jesp.2023.297344>
  17. Helmy, Y. A., Krücken, J., Nöckler, K., von Samson-Himmelstjerna, G., & Zessin, K. H., Molecular epidemiology of *Cryptosporidium* in livestock animals and humans in the Ismailia province of Egypt. *Veterinary Parasitology*. 2013; 193(1–3), 15–24. <https://doi.org/10.1016/j.vetpar.2012.12.015>
  18. Shalaby, N., & Shalaby, N., *Cryptosporidium parvum* infection among Egyptian school children. *Journal of the Egyptian Society of Parasitology*. 2015; 45(1), 125–131. [https://journals.ekb.eg/article\\_89720.html](https://journals.ekb.eg/article_89720.html)
  19. El-Nadi, N. A. F., Omran, E. K., Ahmed, N. S., & Fadel, E. F., Current Status of Intestinal Parasites among Elementary School children in Sohag, Egypt. *The Journal of Advances in Parasitology*. 2017; 4(2), 33–40. <https://doi.org/10.17582/journal.jap/2017/4.2.33.40>
  20. Dyab, A. K., Hassan, T. M., & Mohamed, Y. M., Risk Factors for Cryptosporidiosis Infection in Children. *Aljouf University Medical Journal*. 2018; 5(2), 11–16. <https://doi.org/10.12816/0055034>
  21. Chonchol, M., Neutrophil dysfunction and infection risk in end-stage renal disease. *Seminars in Dialysis*. 2006; 19(4), 291–296. <https://doi.org/10.1111/j.1525-139X.2006.00175.x>
  22. Bagatini, M. D., Cardoso, A. M. H., Santos, A. A. Dos, & Carvalho, F. B., Immune System and Chronic Diseases. *Journal of Immunology Research*. 2017. <https://doi.org/10.1155/2017/4284327>
  23. Rubinow, K. B., & Rubinow, D. R., In immune defense: redefining the role of the immune system in chronic disease. *Dialogues in clinical neuroscience*. 2017; 19(1), 19–26. <https://doi.org/10.31887/DCNS.2017.19.1/drubino>
  24. El-kady, A. M., Fahmi, Y., Tolba, M., Hashim, A. K. A., & Hassan, A. A., *Cryptosporidium* infection in chronic kidney disease patients undergoing hemodialysis in Egypt. *Journal of Parasitic Diseases*. 2018; 42(4), 630–635. <https://doi.org/10.1007/s12639-018-1046-3>
  25. Ahmed, A., El-Mawgood, A., Mohammed, M., El-Nazer, A., Saad Mohamed, H., & Gaballa, M. R., Intestinal Parasites and Microsporidia in Patients with Chronic Kidney

- Disease, Sohag Governmental Hospitals. *Journal of the Egyptian Society of Parasitology*. 2022; 52(2), 316. <https://doi.org/10.21608/jesp.2022.257460>
26. Morsy, S. M., Ghallab, M. M. I., Ismail, M. A. M., & Ismail, A. R., Opportunistic Protozoa Coinfected with *Helicobacter Pylori* Among Egyptian Diabetic Patients. *Journal of the Egyptian Society of Parasitology*. 2024; 54 (1). <https://doi.org/10.21608/jesp.2024.351361>
27. Mohamed, R., Abdaljelil, N. H., Mohammed, A. R., & Sanadeki, M. M., Different parasitic infections detected in children with diabetes mellitus in Minia governorate, Egypt. *Minia Journal of Medical Research*. 2024. <https://doi.org/10.21608/mjmr.2024.321960.1803>
28. Łanocha, A., Łanocha-Arendarczyk, N., Wilczyńska, D., Zdziarska, B., & Kosik-Bogacka, D., Protozoan Intestinal Parasitic Infection in Patients with Hematological Malignancies. *Journal of Clinical Medicine*. 2022; 11(10). <https://doi.org/10.3390/jcm11102847>
29. Certad, G., Is *Cryptosporidium* a hijacker able to drive cancer cell proliferation? *Food and Waterborne Parasitology*. 2022; 27. <https://doi.org/10.1016/j.fawpar.2022.e00153>
30. Mohammad, S. M., Ali, M., Abdel-rahman, S. A., Moustafa, R. A., & Salama, M. A., Molecular prevalence of *Cryptosporidium* isolates among Egyptian children with cancer. *Journal of Parasitic Diseases*. 2021; 45(3), 746–753. <https://doi.org/10.1007/s12639-020-01345-y>
31. Seleem, N. I., Abd, N., El-Nadi, E.-F., Eldin, E., Hassan, N., & Gaballah, M. R., Case-Control Study of Intestinal Parasites in Patients with Intestinal Cancer in Sohag, Egypt. *Journal of The Egyptian Society of Parasitology*. 2024; 54(2), 319-324, 54(2), 319–324. [https://journals.ekb.eg/article\\_373538\\_8c4eaa49dfb6adc04d062f189a407482.pdf](https://journals.ekb.eg/article_373538_8c4eaa49dfb6adc04d062f189a407482.pdf)
32. Zhang, N., Yu, X., Zhang, H., Cui, L., Li, X., Zhang, X., Gong, P., Li, J., Li, Z., Wang, X., Li, X., Li, T., Liu, X., Yu, Y., & Zhang, X., Prevalence and genotyping of *Cryptosporidium parvum* in gastrointestinal cancer patients. *Journal of Cancer*. 2020; 11(11), 3334–3339. <https://doi.org/10.7150/jca.42393>
33. Mohamed, S., El-Hady, H., & Ahmed, A., Evaluation of Immunochromatographic Assay for Diagnosis of Cryptosporidiosis. *Journal of the Egyptian Society of Parasitology*. 2020; 50(3), 477–482. <https://doi.org/10.21608/jesp.2020.131060>
34. Sanad, M. M., Thagfan, F. A., Al-Olayan, E. M., Almogren, A., Al-Hammaad, A., Al-Mawash, A., & Mohamed, A. A., Opportunistic coccidian parasites among Saudi cancer patients presenting with diarrhea: prevalence and immune status. *Research Journal of Parasitology*. 2014; 9(2), 55–63. <https://www.cabidigitallibrary.org/doi/full/10.5555/20153112643>
35. Dyab, A., Mohamed, R., Mahmoud, A., Khalifa, M., Molecular detection of (TNF $\alpha$ ) and (IL-4) in helminthic and protozoan infected patients in relation to COVID-19 vaccines in Assiut, Egypt. *Parasitologists United Journal*. 2024; 17(3). <http://doi:10.21608/puj.2024.311275.1262>
36. Hawash, Y., Ismail, K. H., & Abdel-Wahab, M., Shift in parasitic infections during the Corona pandemic: A hospital-based retrospective study. *Tropical Biomedicine*. 2021; 38(2), 94–101. <https://doi.org/10.47665/TB.38.2.038>
37. Knox, M. A., Garcia-R, J. C., Ogbuigwe, P., Pita, A., Velathanthiri, N., & Hayman, D. T. S., Absence of *Cryptosporidium hominis* and dominance of zoonotic *Cryptosporidium* species in patients after Covid-19 restrictions in Auckland, New Zealand. *Parasitology*. 2021; 148(11), 1288–1292. <https://doi.org/10.1017/S0031182021000974>
38. Adamson, J. P., Chalmers, R. M., Thomas, D. R., Elwin, K., Robinson, G., & Barrasa, A., Impact of the COVID-19 restrictions on the epidemiology of *Cryptosporidium* spp. in England and Wales, 2015–2021: a time series analysis. *Journal of Medical Microbiology*. 2023; 72(6). <https://doi.org/10.1099/jmm.0.001693>

39. Aschwanden, D., Strickhouser, J. E., Sesker, A. A., Lee, J. H., Luchetti, M., Terracciano, A., & Sutin, A. R., Preventive Behaviors During the COVID-19 Pandemic: Associations with Perceived Behavioral Control, Attitudes, and Subjective Norm. *Frontiers in Public Health*. 2021; 9. <https://doi.org/10.3389/fpubh.2021.662835>
40. Onyeaka, H., Anumudu, C. K., Al-Sharify, Z. T., Egele-Godswill, E., & Mbaegbu, P., COVID-19 pandemic: A review of the global lockdown and its far-reaching effects. *Science Progress*. 2021; 104(2). <https://doi.org/10.1177/00368504211019854>
41. Hu, Y., & Lü, W., Meaning in life and health behavior habits during the COVID-19 pandemic: Mediating role of health values and moderating role of conscientiousness. *Current Psychology*. 2024; 43(16), 14935–14943. <https://doi.org/10.1007/s12144-022-04020-y>
42. Kazempour, M., Izadi, H., Chouhdari, A., & Rezaeifard, M., Anti-inflammatory Effect of Metronidazole in Hospitalized Patients with Pneumonia due to COVID-19. *Iranian Journal of Pharmaceutical Research*. 2021; 20(3), 532–540. <https://doi.org/10.22037/IJPR.2021.114567.14917>
43. Rajter, J. C., Sherman, M. S., Fatteh, N., Vogel, F., Sacks, J., & Rajter, J. J., Use of Ivermectin Is Associated with Lower Mortality in Hospitalized Patients with Coronavirus Disease 2019: The Ivermectin in COVID Nineteen Study. *Chest*. 2021; 159(1), 85–92. <https://doi.org/10.1016/j.chest.2020.10.009>
44. Abuelazm, M., Ghanem, A., Awad, A. K., Farahat, R. A., Labieb, F., Katamesh, B. E., & Abdelazeem, B., The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Clinical Drug Investigation*. 2022; 42(12), 1031–1047. <https://doi.org/10.1007/s40261-022-01213-y>
45. El Achkar, H., Ghandour, L., Farran, S., & Araj, G. F., Prevalence of intestinal parasites during pre- and post-COVID-19 pandemic at a tertiary care center in Lebanon. *Journal of Infection in Developing Countries*. 2023; 17(6), 826–831. <https://doi.org/10.3855/jidc.17495>
46. Abd El Kader, N. M., Blanco, M. A., Ali-Tammam, M., Abd El Ghaffar, A. E. R. B., Osman, A., Sheikh, N. El, Rubio, J. M., & De Fuentes, I., Detection of *Cryptosporidium parvum* and *Cryptosporidium hominis* in human patients in Cairo, Egypt. *Parasitology Research*. 2012; 110(1), 161–166. <https://doi.org/10.1007/s00436-011-2465-6>
47. El-Badry, A. A., Al-Antably, A. S. A., Hassan, M. A., Hanafy, N. A., & Abu-Sarea, E. Y., Molecular seasonal, age and gender distributions of *Cryptosporidium* in diarrheic Egyptians: distinct endemicity. *European Journal of Clinical Microbiology and Infectious Diseases*. 2015; 34(12), 2447–2453. <https://doi.org/10.1007/s10096-015-2502-y>
48. Naguib, D., El-Gohary, A. H., Roellig, D., Mohamed, A. A., Arafat, N., Wang, Y., Feng, Y., & Xiao, L., Molecular characterization of *Cryptosporidium* spp. and *Giardia duodenalis* in children in Egypt. *Parasites and Vectors*. 2018; 11(1). <https://doi.org/10.1186/s13071-018-2981-7>
49. Wahed, M. A. A., Shehab, Y. E. A., Abou-Seri, H. M., & Awad, Y. M. M., Clinical and Laboratory Diagnosis of Cryptosporidiosis among Children with Acute Gastroenteritis at a Tertiary Hospital, Cairo, Egypt. *Journal of Tropical Pediatrics*. 2021; 67(3). <https://doi.org/10.1093/tropej/fmab064>
50. Amin, N., Raafat, A., & Morsy, S., Detection rate and genotyping of *Cryptosporidium* spp. and its relation to copro TNF- $\alpha$  in elderly Egyptians attending outpatient clinics of Cairo University Hospitals. *Parasitologists United Journal*. 2021; 14(1), 77–85. <https://doi.org/10.21608/puj.2021.51301.1095>
51. Ghallab, M. M. I., Ismail, M. A. M., Haydara, T., & Morsy, S. M., Cryptosporidiosis: Molecular Analysis, Risk Factors and Seasonal Abundance in Immunocompetent and Immunocompromised Patients, Kafrelsheikh University Hospitals. *Journal of the Egyptian Society of Parasitology*. 2022; 52(1), 117–122. [https://jesp.journals.ekb.eg/article\\_235822\\_f63b48fa86d70b75625ba28caf428d9d.pdf](https://jesp.journals.ekb.eg/article_235822_f63b48fa86d70b75625ba28caf428d9d.pdf)

52. Ibrahim, H. S., Shehab, A. Y., Allam, A. F., Mohamed, M. A., Farag, H. F., & Tolba, M. M., Detection and Molecular Identification of *Cryptosporidium* Species Among Children with Malignancies. *Acta Parasitologica*. 2021; 66(2), 377–383. <https://doi.org/10.1007/s11686-020-00250-x>
53. Merdaw, M., Thabit, M., Al-Zubaidi, S., Basil, D., & Sadoon, H., Genotyping of *Cryptosporidium* spp. Isolated from Human and Cattle in Baghdad Province, Iraq. *Indian Journal of Natural Sciences*. 2018; 9(51), 15925–15932. <https://www.researchgate.net/publication/329591206>
54. Al-Warid, H. S., Al-Saqur, I. M., & Mahmood, S. H., The Detection Limit of PCR Amplification for *Cryptosporidium* spp. Oocysts in Fecal Samples. *National Academy Science Letters*. 2019; 42(5), 423–424. <https://doi.org/10.1007/s40009-018-0770-7>
55. Adam, K. Y., Ismail, A. A., Masri, M. A., & Gameel, A. A., First report and molecular characterization of *Cryptosporidium* spp. In humans and animals in Khartoum state, Sudan. *Veterinary World*. 2019; 12(1), 183–189. <https://doi.org/10.14202/vetworld.2019.183-189>
56. Abdou, N. E. M. I., AlAzemi, M. S., Al-Sayegh, M. T., & Majeed, Q. A. H., Performance of diagnostic assays used to detect *Cryptosporidium* oocysts in faecal samples of cattle in Kuwait and genotyping of *Cryptosporidium* species. *BMC Veterinary Research*. 2022; 18(1). <https://doi.org/10.1186/s12917-022-03435-w>
57. Gawad, S. S. A., Ismail, M. A. M., Imam, N. F. A., Eassa, A. H. A., & Abu-Sarea, E. Y., Detection of *Cryptosporidium* spp. in diarrheic immunocompetent patients in Beni-Suef, Egypt: Insight into epidemiology and diagnosis. *Korean Journal of Parasitology*. 2018; 56(2), 113–119. <https://doi.org/10.3347/kjp.2018.56.2.113>
58. Selvakumar, N., Rahman, F., Rajasekaran, S., Narayanan, P. R., & Frieden, T. R., Inefficiency of 0.3% carbol fuchsin in Ziehl-Neelsen staining for detecting acid-fast bacilli. *Journal of Clinical Microbiology*. 2002 ;40(8), 3041–3043. <https://doi.org/10.1128/JCM.40.8.3041-3043.2002>
59. Chen, Y., Wu, Y., Qin, H., Xu, H., & Zhang, L., Prevalence of *Cryptosporidium* infection in children from China: a systematic review and meta-analysis. *Acta Tropica*. 2023; 244. <https://doi.org/10.1016/j.actatropica.2023.106958>
60. Laude, A., Valot, S., Desoubreux, G., Argy, N., Nourrisson, C., Pomares, C., Machouart, M., Le Govic, Y., Dalle, F., Botterel, F., Bourgeois, N., Cateau, E., Leterrier, M., Le Pape, P., & Morio, F., Is real-time PCR-based diagnosis similar in performance to routine parasitological examination for the identification of *Giardia intestinalis*, *Cryptosporidium parvum*/*Cryptosporidium hominis* and *Entamoeba histolytica* from stool samples? Evaluation of a new commercial multiplex PCR assay and literature review. *Clinical Microbiology and Infection*. 2016; 22(2), 190.e1-190.e8. <https://doi.org/10.1016/j.cmi.2015.10.019>
61. Mahmoudi, M., Tappeh, K. H., Abasi, E., & Aminpour, A., Utility of different diagnostic tools for detection of *Cryptosporidium* in children with diarrhea. *Archives of Pediatric Infectious Diseases*. 2020; 8(1). <https://doi.org/10.5812/pedinfect.92033>
62. Dong, S., Yang, Y., Wang, Y., Yang, D., Yang, Y., Shi, Y., Li, C., Li, L., Chen, Y., Jiang, Q., & Zhou, Y., Prevalence of *Cryptosporidium* Infection in the Global Population: A Systematic Review and Meta-analysis. *Acta Parasitologica*. 2020; 65(4), 882–889. <https://doi.org/10.2478/s11686-020-00230-1>
63. Castro-Hermida, J. A., García-Prevedo, I., Almeida, A., González-Warleta, M., Correia Da Costa, J. M., & Mezo, M., Presence of *Cryptosporidium* spp. and *Giardia duodenalis* through drinking water. *Science of the Total Environment*. 2008; 405(1–3), 45–53. <https://doi.org/10.1016/j.scitotenv.2008.06.040>
64. Dwi, M., Putra, E., Sugih Utami, W., Agustina, D., Hermansyah, B., & Kusuma, I. F., Risk Factors of *Cryptosporidium* spp. Infection Through Drinking Water Sources in Farming Communities in Sukowono District

- Jember Regency. *Jember Medical Journal*. 2023; 2(1). <https://doi.org/10.19184/jmj.v2i1.204>
65. Xiao, L., & Feng, Y., Zoonotic cryptosporidiosis. *FEMS Immunology and Medical Microbiology*. 2008; 52(3), 309–323. <https://doi.org/10.1111/j.1574-695X.2008.00377.x>
66. Boughattas, S., Behnke, J. M., Al-Sadeq, D., Ismail, A., & Abu-Madi, M., *Cryptosporidium* spp., prevalence, molecular characterisation and socio-demographic risk factors among immigrants in Qatar. *PLoS Neglected Tropical Diseases*. 2019; 13(10). <https://doi.org/10.1371/journal.pntd.0007750>
67. Krumkamp, R., Aldrich, C., Maiga-Ascofare, O., Mbwana, J., Rakotozandrindrainy, N., Borrmann, S., Caccio, S. M., Rakotozandrindrainy, R., Adegnika, A. A., Lusingu, J. P. A., Amuasi, J., May, J., Eibach, D., Stark, T., Dekker, D., Jaeger, A., Hogan, B., Lamshöft, M., Thye, T., ... Sannella, A. R., Transmission of *Cryptosporidium* Species among Human and Animal Local Contact Networks in Sub-Saharan Africa: A Multicountry Study. *Clinical Infectious Diseases*. 2020; 72(8), 1358–1366. <https://doi.org/10.1093/cid/ciaa223>
68. El-Sherbini, G. T., & Mohammad, K. A., Zoonotic cryptosporidiosis in man and animal in farms, Giza Governorate, Egypt. *Journal of the Egyptian Society of Parasitology*. 2006; 36(2), 49–58. <https://europepmc.org/article/med/17366871>
69. Izadi, M., Jonaidi-Jafari, N., Saburi, A., Eyni, H., Rezaieanesh, M. R., & Ranjbar, R., Cryptosporidiosis in Iranian farm workers and their household members: A hypothesis about possible zoonotic transmission. *Journal of Tropical Medicine*, 2014. <https://doi.org/10.1155/2014/405875>
70. Khan, A., Shams, S., Khan, S., Khan, M. I., Khan, S., & Ali, A., Evaluation of prevalence and risk factors associated with *Cryptosporidium* infection in rural population of district Buner, Pakistan. *PLoS ONE*. 2019; 14(1). <https://doi.org/10.1371/journal.pone.0209188>
71. Sinyangwe, N. N., Siwila, J., Muma, J. B., Chola, M., & Michelo, C., Factors Associated with *Cryptosporidium* Infection Among Adult HIV Positive Population in Contact with Livestock in Namwala District, Zambia. *Frontiers in Public Health*. 2020; 8. <https://doi.org/10.3389/fpubh.2020.00074>